CDKN2A and neoplasm: Although the same GBM associated genes were often targeted by recurrent aberrations (e.g. amplification of EGFR, homozygous deletion of CDKN2A or chromosome 10; Fig 1c), we did not detect any common breakpoints between different tumours for a given targeted gene, highlighting the uniqueness of each patient’s tumour genome (not shown).